Clinical trials: Oropharyngeal Cancers
Head and Neck Cancer
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00509665
- Testing
- doxorubicin hydrochloride, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Head and Neck Cancer
Contact Allergies to Dental Metal as a Possible Risk Factor for Oral Cancer
RATIONALE: Gathering information about allergies to metals may help doctors learn whether having an allergy to metal used in dental work increases the risk of developing oral cancer.
- Trial name
- NCT00693550
- Testing
- metal patch tests
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
This phase II trial is studying how well cediranib maleate works in treating patients with recurrent or newly diagnosed metastatic head and neck cancer.
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT00458978
- Testing
- Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fludeoxyglucose F 18 (FDG) PET scans, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00757549
- Testing
- cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Oropharynx Cancer, Oral Cancer
Very Intense Radiotherapy-chemotherapy Regimen in Advanced HNSCC
Altered fractionated radiotherapy and concomitant radio-chemotherapy have been shown to be two possibilities for improving efficacy of radiotherapy in locally advanced head and neck carcinomas.
- Conditions
- Oropharynx Cancer, Oral Cancer, Hypopharynx Cancer, Larynx Cancer
- Trial name
- NCT00162708
- Testing
- Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID), Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID), CDDP, 5 Fu
- Where
- 3 sites in France
- Volunteers
- 120 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Oropharyngeal Dysphagia
REVIVE Prospective Registry Cohort Study
The main purpose of this registry is to collect observational, long-term safety and effectiveness data in participants who have received iltamiocel as part of the blinded portion of the REVIVE clinical study.
- Trial name
- NCT07429890
- Testing
- Other: No Intervention (subjects were previously treated with Iltamiocel). This is a observational study and all participants will be observed with no intervention.
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of California, Davis
Head and Neck Cancer
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002735
- Testing
- Induction chemotherapy, cisplatin, fluorouracil
- Where
- 18 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
Oropharynx Cancer
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to…
- Trial name
- NCT05800574
- Testing
- Radiation therapy (5 days for 7 weeks), Radiation therapy (5 days for 6 weeks), Cisplatin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Fox Chase Cancer Center
Head and Neck Cancer
Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat
RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck.
- Trial name
- NCT00012168
- Testing
- isosulfan blue, polymerase chain reaction, immunohistochemistry staining method
- Where
- United States
- Sponsor
- NYU Langone Health
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
This is an open-label study designed to evaluate safety and efficacy of enoblituzumab in combination with MGA012 or MGD013 in first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and…
- Trial name
- NCT04129320
- Testing
- enoblituzumab, MGA012, MGD013
- Sponsor
- MacroGenics